- Home
- ESAB vs BBIO Comparison
ESAB vs BBIO Comparison
Compare ESAB & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESAB
- BBIO
- Stock Information
- Founded
- ESAB 1904
- BBIO 2015
- Country
- ESAB United States
- BBIO United States
- Employees
- ESAB N/A
- BBIO N/A
- Industry
- ESAB Office Equipment/Supplies/Services
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ESAB Industrials
- BBIO Health Care
- Exchange
- ESAB Nasdaq
- BBIO Nasdaq
- Market Cap
- ESAB 7.8B
- BBIO 7.6B
- IPO Year
- ESAB N/A
- BBIO 2019
- Fundamental
- Price
- ESAB $115.59
- BBIO $41.73
- Analyst Decision
- ESAB Buy
- BBIO Strong Buy
- Analyst Count
- ESAB 8
- BBIO 13
- Target Price
- ESAB $136.50
- BBIO $56.67
- AVG Volume (30 Days)
- ESAB 251.0K
- BBIO 2.5M
- Earning Date
- ESAB 08-01-2025
- BBIO 07-31-2025
- Dividend Yield
- ESAB 0.35%
- BBIO N/A
- EPS Growth
- ESAB 16.34
- BBIO N/A
- EPS
- ESAB 4.43
- BBIO N/A
- Revenue
- ESAB $2,729,197,000.00
- BBIO $127,415,000.00
- Revenue This Year
- ESAB N/A
- BBIO $102.05
- Revenue Next Year
- ESAB $5.55
- BBIO $54.69
- P/E Ratio
- ESAB $25.96
- BBIO N/A
- Revenue Growth
- ESAB N/A
- BBIO N/A
- 52 Week Low
- ESAB $88.54
- BBIO $21.62
- 52 Week High
- ESAB $135.97
- BBIO $41.90
- Technical
- Relative Strength Index (RSI)
- ESAB 31.39
- BBIO 69.82
- Support Level
- ESAB $122.83
- BBIO $39.65
- Resistance Level
- ESAB $125.95
- BBIO $41.36
- Average True Range (ATR)
- ESAB 2.65
- BBIO 1.51
- MACD
- ESAB -1.20
- BBIO 0.35
- Stochastic Oscillator
- ESAB 8.12
- BBIO 97.37
About ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.